Symbicort Turbuhaler analogs of the drug. Price

Symbicort Turbuhaler is an imported drug produced by the Swedish pharmaceutical company AB Astrazeneca. This medication belongs to therapeutic group of combined bronchodilators beta2-adrenergic agonists with a glucocorticosteroid spectrum of action.

Symbicort Turbuhaler, like most of its analog drugs, is prescribed for a course admission for complex treatment of asthma, as well as relief of attacks of bronchial spasm during the next exacerbation this ailment. The average cost of this drug is from 855 to 1063 rubles. for 1 bottle for 60 doses.

Domestic and imported analogues of the product

Symbicort Turbuhaler is not the only selective beta2-adrenergic agonist that is used to improve the general well-being of patients with bronchial asthma. There are domestic and imported drugs with similar properties to improve the functions of the respiratory system and eliminate the local inflammatory process.

Berodual

Berodual is a dose-dependent medication that is analogous to the drug Symbicort Turbuhaler.

These drugs have the following pharmacological similarities:

• both drugs belong to the same therapeutic group of bronchodilating agents that have a direct effect on the sensitive receptors of the bronchial tree;
• Berodual and Symbicort Turbuhaler are intended for the systemic treatment of bronchial asthma and chronic obstructive pulmonary disease;
• these medicines are developed for local use by inhalation of the respiratory system with the delivery of active substances directly to the focus of the pathological process;
• the composition of the preparations Berodual and Symbicort Turbuhaler contains chemicals that equally provide the fastest possible implementation of bronchodilator properties;
• both medicines improve the functional state of the lungs in patients with emphysema of various origins, as well as obstructive processes;
• Berodual and Symbicort Turbuhaler are equally effective in relaxing the smooth muscles of the vessels and bronchi, which are spasmodic instantly an allergic reaction (for example, in the case of severe hypersensitivity to certain foods, biological poisons and chemical substances);
• drugs of these types are indicated for use only under the supervision of medical personnel;
• means for inhalation Berodual and Symbicort Turbuhaler can cause allergic reactions in patients whose body is hypersensitive to the constituent substances of these medicines.

These drugs can be used for the treatment and prevention of bronchial spasms in children, adults and elderly people.

At the same time, the medicines Berodual and Symbicort Turbuhaler have not only pharmacological similarities, but also a number of the following differences:

• the drug Symbicort Turbuhaler is available in the form of a granular powder, which is inhaled during inhalation in the bronchi in small therapeutic doses, and the medication Berodual is produced in the form of a liquid transparent solution;
• the combined composition of these medicines differs in that the inhalation liquid Berodual contains the active components fenoterol and ipratropium bromide in the form of monohydrate, and the pharmacological properties of Symbicort Turbuhaler are provided by micronized budesonide and the substance formoterol;
• Berodual is produced by the German pharmaceutical company Berniger Ingelheim, Hamburg;
• Symbicort Turbuhaler drug is approved for therapeutic or prophylactic use only for patients older 12 years old, and the bronchodilator Berodual can be used to treat patients younger than 6 years old, but weighing at least 22 kg;
• liquid solution Berodual is filled in different models of stationary and portable nebulizers, and Symbicort Turbuhaler sold only with a branded inhaler, which is designed to deliver granular powder inside the lower respiratory tract.

The above drugs are powerful medicines. Therefore, the dosage regimen with these means is selected only by a pulmonologist or therapist with special control over the general condition of the patient.

Pulmicort

Symbicort Turbuhaler (analogues of the drug have a different price category) is a medication created for a course admission, but in cases of immediate hypersensitivity reaction can be used as an antispasmodic agent of rapid actions. The drug Pulmicort works in the same way.

These medicines have the following similarities in pharmacological characteristics:

• drugs Pulmicort and Symbicort Turbuhaler are inhalants of local action, showing therapeutic properties exclusively in the organs of the respiratory system;
• these medicines contain the same active ingredient in the form of micronized budesonide;
• medicines of these types belong to the category of bronchodilator glucocorticosteroids;
• drugs Pulmicort and Symbicort Turbuhaler can be used not only for treatment bronchial asthma, but are also used for the timely prevention of the occurrence of another an attack of suffocation;
• the active substance of these medicines is characterized by rapid absorption, which is confirmed by the biological the availability of budesonide in the blood plasma at the level of 15% (this indicator is recorded immediately after completion inhalation);
• drugs Pulmicort and Symbicort Turbuhaler have the same binding to plasma proteins, which is within 90%;
• both medicines are produced by the same pharmaceutical company Astrazeneca, Sweden;
• metabolic transformation of the active component of these drugs occurs with the participation of a similar enzyme substance CYP3A4;
• drugs Pulmicort and Symbicort Turbuhaler have the same effect on the body of patients with liver dysfunctions, slowing down the process of biochemical decomposition of budesonide.

These drugs have the following distinctive features:

• the form of release of the drug Pulmicort is a white suspension, and the inhalation agent Symbicort Turbuhaler is a granular powder;
• the drug Symbicort Turbuhaler contains an additional substance in the form of formoterol, and there is no such component in the inhalation drug Pulmicort;
• in the medicine Symbicort Turbuhaler 1 therapeutic dose is 80 or 160 mcg of budesonide, and in Pulmicort this substance is presented in dosages of 250 and 500 mcg;
• Pulmicort in the form of a suspension is approved for use for the treatment of children aged 6 months, and Symbicort Turbuhaler is prescribed only to patients 12 years of age and older.

Symbicort Turbuhaler (analogs of the drug are available by prescription) is a medication with a lower concentration of the active ingredient. In this case, the inhalation agent Pulmicort is more suitable for patients with severe forms of bronchial asthma and obstructive processes in the lungs.

Berodual N

The drug Berodual N and the drug Symbicort Turbuhaler have the following pharmacological similarities:

• both medicines have bronchodilator properties, relax the muscle fibers of smooth muscles, facilitate breathing during a spasm;
• these drugs have a local effect directly in the tissues of the lower respiratory tract;
• the constituent substances of Berodual N and the medicine Symbicort Turbuhaler help to eliminate the inflammatory process in the lungs and the structure of the bronchial tree;
• the delivery of the active components of these drugs is carried out by the inhalation method;
• both drugs are indicated for use for the prevention and course of treatment of bronchial asthma, obstructive processes in the organs of the respiratory system.

The drugs Berodual N and Symbicort Turbuhaler have not only therapeutic similarities, but also significant differences in the form of the following characteristics:

• the medication Berodual N contains other active ingredients in the form of fenoterol and ipratropium bromide;
• the drug Berodual N has the form of a yellowish liquid, which is delivered to the lungs using a metal aerosol can under pressure;
• Berodual N is produced by the German pharmaceutical company Boehringer Ingelheim, Hamburg;
• inhalation agent Berodual N is not a glucocorticosteroid medication, which reduces the number of side effects;
• Berodual N is prescribed for patients over 6 years old, and Symbicort Turbuhaler is prescribed only for patients over 12 years old.

The advantage of the drug Berodual N is that it can be used to treat young children, and its form of release in the form of an aerosol greatly facilitates the therapeutic process.

Salbutamol

Symbicort Turbuhaler (analogues of the drug have exactly the same therapeutic efficacy) and the drug Salbutamol have the following pharmacological similarities:

• both medicines belong to a single pharmacotherapeutic group of beta2-adrenergic agonists with bronchodilator properties;
• these drugs have the same indications for their use in order to relieve an acute attack of suffocation caused by bronchial spasm;
• the medicines Salbutamol and Symbicort Turbuhaler are used for the complex treatment of pulmonary emphysema and complicated forms of chronic bronchitis;
• both drugs are used exclusively by inhalation by injecting an active substance into the structure of the bronchial tree;
• medicines Salbutamol and Symbicort Turbuhaler have therapeutic properties in the form of eliminating signs of an allergic reaction caused by an increased sensitivity of the body to histamine;
• these drugs are prescribed with extreme caution to patients diagnosed with severe liver disease.

Medicines Salbutamol and Symbicort Turbuhaler have not only pharmacological similarities, but also the following differences:

• the active ingredient of the inhalation medication Salbutamol is a chemical compound of salbutamol sulfate at a dosage of 100 μg per 1 dose;
• the drug Salbutamol is available in the form of an aerosol that sprays a white liquid suspension;
• the drug Salbutamol prevents further synthesis of histamine, which aggravates bronchial spasm, and Symbicort Turbuhaler does not have similar properties;
• Salbutamol inhalation aerosol is produced by the Chinese pharmaceutical company Jevim Pharmaceutical.

The advantage of Salbutamol over Symbicort Turbuhaler is that the first the medication not only relieves bronchial spasm, but also acts as a local antihistamine funds.

DuoResp Spiromax

Symbicort Turbuhaler (analogues of the drug are produced in the form of a suspension and liquid aerosols) and the drug DuoResp Spiromax have the following similarities in pharmacological characteristics:

• both drugs are produced in the form of a white granular powder intended for metered-dose inhalation;
• DuoResp Spiromax and Symbicort Turbuhaler preparations are produced on the basis of the same active ingredients in the form of micronized budesonide and formoterol;
• these medicines have a combined chemical composition;
• inhalation agents DuoResp Spiromax and Symbicort Turbuhaler are indicated for use for complex treatment and prevention of bronchial asthma attacks;
• these drugs increase the functional ability of the lower respiratory tract;
• both drugs belong to the category of bronchodilator drugs with the addition of glucocorticosteroids;
• granular powder for inhalation DuoResp Spiromax and Symbicort Turbuhaler not only stop the spasm of the smooth muscles of the bronchi, but also contribute to the elimination of the focus of the inflammatory process;
• drugs of these types can be used for the symptomatic treatment of obstructive pulmonary disease with a chronic course;
• both medicines can cause side effects in the form of local and more extensive allergic reactions.

Medicines DuoResp Spiromax and Symbicort Turbuhaler have the following distinctive features:

• the drug DuoResp Spiromax is contraindicated in patients under 18 years of age, and Symbicort Turbuhaler does not have such restrictions for use;
• the drug DuoResp Spiromax contains a large concentration of the active substance budesonide in 1 inhalation dose (160 and 320 μg);
• the drug DuoResp Spiromax is produced by the Israeli pharmaceutical company Teva Pharmaceutical.

The main disadvantage of the drug for inhalation DuoResp Spiromax is that its cannot be used for the treatment of bronchial asthma and chronic obstructive processes in the lungs in children. Otherwise, these medicines are interchangeable.

Respiforb Combi

Respiforb Combi is the Russian analogue of Symbicort Turbuhaler.

These medicines have the following pharmacological similarities:

• both drugs contain the same active ingredients in the form of formoterol and budesonide;
• these medicines belong to a single therapeutic group of bronchodilators with a pronounced anti-inflammatory effect due to the presence of a glucocorticosteroid component;
• Respiforb Kombi and Symbicort Turbuhaler are equally effective in the treatment of bronchial asthma, prevention of asthma attacks caused by allergic spasm of the bronchi;
• both drugs are indicated for use as inhalation agents;
• medicines Respiforb Kombi and Symbicort Turbuhaler act locally, increasing the functionality of the lower respiratory tract;
• drugs of these types are equally contraindicated in patients with individual sensitivity of the body to budesonide and formoterol;
• inhalation agents Respiforb Combi and Symbicort Turbuhaler are approved for use in the treatment of children.

Bronchodilators of these types have the following minor differences:

• Respiforb Combi is available in the form of capsules containing white powder used for inhalation of the respiratory system;
• the drug Respiforb Kombi is produced by the Russian pharmaceutical company Biopharm LLC;
• Respiforb Combi has a higher concentration of active substances in 1 inhalation dose;
• Symbicort Turbuhaler medication can only be used to treat patients over 12 years old, and at what age to use Respiforb Combi is determined by the attending physician on an individual basis.

Medicines Respiforb Combi and Symbicort Turbuhaler can be considered completely interchangeable analogues. At the same time, the Russian drug is more affordable from a material point of view.

Foradil Combi

Foradil Combi is a medicine used for inhalation of the lower respiratory tract.

This medication has the following pharmacological similarities with the analogue drug Symbicort Turbuhaler:

• both drugs contain the same active ingredients in the form of formoterol and budesonide;
• these medicines belong to a single therapeutic group of bronchodilators with a combined composition, which have glucocorticosteroid properties;
• Foradil Combi and Symbicort Turbuhaler have a quick therapeutic effect in terms of expanding the lumen of the bronchi, relieving spasm of smooth muscles, eliminating symptoms of suffocation;
• drugs of these types are used for the treatment and prevention of bronchial asthma, improvement of general well-being in patients suffering from chronic obstructive pulmonary disease;
• both drugs are taken orally by inhalation inhalation with the delivery of active substances directly to the structure of the bronchial tree;
• medicines Foradil Combi and Symbicort Turbuhaler are dose-dependent bronchodilators, but at the same time provide a prolonged therapeutic effect even after 1 inhalation;
• these drugs are equally contraindicated in patients with pulmonary tuberculosis and severe pathologies of the cardiovascular system.

Medicines of these types are considered completely interchangeable analogues. The distinctive features of these medicines include the fact that Foradil Kombi is produced in the form of capsules, inside of which there is a powder with active substances of different types. Also, this drug is produced by the Swiss pharmaceutical company Novartis Pharma.

Prices

The table below lists drugs analogs of the medicinal product Symbicort Turbuhaler, and also indicates their average cost in retail pharmacy chains.

Name of the medication	Price range
Berodual	From 244 to 252 rubles. for 1 bottle with a capacity of 20 ml
Pulmicort	From 719 to 920 rubles. for 20 ampoules of 2 ml
Berodual N	From 429 to 456 rub. for a 200-dose aerosol can
Salbutamol	From 83 to 120 rubles. for 1 bottle with a capacity of 12 ml
DuoResp Spiromax	From 1363 to 1642 rub. for 1 inhaler for 120 doses

Symbicort Turbuhaler is a drug with bronchodilator and anti-inflammatory properties. This medication belongs to the category of local glucocorticosteroids, which helps to expand the lumen in the structure of the bronchi, has an antispasmodic effect.

A distinctive feature of this drug is that it is designed for inhalation of the lower respiratory tract with dry granular white powder. A patient over the age of 12 years inhales 80 - 160 μg (1 dose) of this medication using a special inhalation device. In retail pharmacy chains, imported and domestic analogues of this drug are sold, which have exactly the same therapeutic properties.

Video about the drug Symbicort

How to use Symbicort Turbuhaler: